Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?

Key Takeaways CRMD's primary revenue driver, DefenCath, posted $167.6M in sales in the first nine months of 2025.CRMD guided 2026 revenues in the range of $300-$320M, with DefenCath sales expected to be $150-$170 million.CRMD's outlook is clouded by cautious guidance, pricing headwinds and high reliance on DefenCath.CorMedix (CRMD) has been riding on the success of its lead product, DefenCath (taurolidine plus heparin), which was approved by the FDA in 2023 as the first and only antimicrobial catheter lock ...